What is it about?
We developed a risk prediction model for cisplatin-induced AKI in patients with head and neck cancer who received postoperative chemoradiotherapy using primary site, cisplatin administration method, serum albumin, and CCr. Patients with risk factors unrelated to the cisplatin administration method should adopt a weekly cisplatin regimen.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
This risk prediction model demonstrated that weekly cisplatin plus raditotherapy is more preferable method for post operative HNSCC patients who were high-risk for recurrence.
Perspectives
Weekly cisplatin plus radiotherapy is one of the standard treatment option for locally advanced head and neck squamous cell carcinoma (HNSCC) patients. And this regimen should be a backbone regimen for future development of chemoradiotherapy for HNSCC.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial, Oral Oncology, July 2024, Elsevier,
DOI: 10.1016/j.oraloncology.2024.106868.
You can read the full text:
Contributors
The following have contributed to this page
